Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical
company developing and delivering novel therapies for the
management of central nervous system (CNS) disorders, today
announced it is joining patient advocacy organizations, including
the National Alliance on Mental Illness (NAMI), to promote
awareness of the importance of mental health during Mental Illness
Awareness Week (MIAW), recognized on Oct. 1-7, 2023.
As part of Axsome’s commitment to developing
innovative therapies that make an impact on the lives of people
suffering from CNS disorders including mental health conditions,
Axsome supports and recognizes events such as MIAW to come together
with other mental health advocates to amplify positive messages,
share resources, and help raise awareness.
NAMI’s theme for MIAW 2023 is “Together We Care.
Together We Share,” chosen to convey “the power of coming together
in community, which can be healing as people gather to share their
experiences,” as well as promote the impact that support and
resources can have for those in need. To learn more about NAMI’s
efforts and plans for MIAW on their website, please check here.
In support of MIAW, Axsome is sponsoring NAMI’s
“Inspiring Hope Through Research” event in Washington D.C. on Oct.
11. As part of NAMI’s commitment to research, each year at this
event NAMI gives an award to a researcher who moves the scientific
understanding and treatment of mental illness forward. This year’s
awardee, Sabine Wilhelm, Ph.D., has been advancing the use of
technology, such as smartphone-based treatments, to help people
with mental health problems. You can learn more about Dr. Wilhelm
here.
Each year one out of every five adults in the
U.S. experience mental illness and, of those, approximately 40% (21
million) had a major depressive episode, characterized by at least
one period of two weeks or longer when for most of the day nearly
every day, they felt depressed or lost interest or pleasure in
daily activities.1 Additionally, only 47.2% of U.S. adults that
experienced a mental illness in 2021 received treatment.2 These
figures highlight the high prevalence and serious impact of
depression and other mental illness on people in the United States,
and the need for improved access to treatment.
The following organizations and their affiliates
provide information about mental health, support networks for those
directly affected and their families, as well as additional
resources:
- American Foundation for
Suicide Prevention (AFSP) (https://afsp.org/). AFSP is a
voluntary health organization dedicated to saving lives and
bringing hope to those affected by suicide, including those who
have experienced a loss.
- Anxiety and Depression
Association of
America (ADAA) (https://adaa.org). ADAA’s
mission focuses on improving quality of life for those with
anxiety, depression, OCD, PTSD, and co-occurring disorders through
education, practice, and research.
- The Depression and Bipolar
Support
Alliance (DBSA) (https://www.dbsalliance.org).
DBSA is a leading national peer-focused mental health organization,
whose mission is to provide hope, help, support, and education for
individuals who live with mood disorders.
- Mental Health America
(MHA) (https://www.mhanational.org). MHA's work is
driven by its commitment to promote mental health as a critical
part of overall wellness, including prevention services for all;
early identification and intervention for those at risk; and
integrated care, services, and support for those who need them,
with recovery as the goal.
- National Alliance on Mental
Illness (NAMI) (https://www.nami.org/). NAMI is
the nation’s largest grassroots mental health organization
dedicated to building better lives for the millions of Americans
affected by mental illness.
If you or a loved one is struggling, speak with
someone today. The 988 Suicide & Crisis Lifeline offers 24/7
call, text, and chat access to trained crisis counselors who can
help people experiencing suicidal, substance use, and/or mental
health crisis, or any other kind of emotional distress. People can
also dial 988 if they are worried about a loved one who may need
crisis support.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical
company developing and delivering novel therapies for central
nervous system (CNS) conditions that have limited treatment
options. Through development of therapeutic options with novel
mechanisms of action, we are transforming the approach to treating
CNS conditions. At Axsome, we are committed to developing products
that meaningfully improve the lives of patients and provide new
therapeutic options for physicians. For more information, please
visit the Company’s website at axsome.com. The Company may
occasionally disseminate material, nonpublic information on the
company website.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
continued commercial success of our Sunosi® and Auvelity® products
and the success of our efforts to obtain any additional
indication(s) with respect to solriamfetol and/or AXS-05; the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation, pace of
enrollment and completion of the trials (including our ability to
fully fund our disclosed clinical trials, which assumes no material
changes to our currently projected revenues or expenses), futility
analyses and receipt of interim results, which are not necessarily
indicative of the final results of our ongoing clinical trials,
and/or data readouts, and the number or type of studies or nature
of results necessary to support the filing of a new drug
application (“NDA”) for any of our current product candidates; our
ability to fund additional clinical trials to continue the
advancement of our product candidates; the timing of and our
ability to obtain and maintain U.S. Food and Drug Administration
(“FDA”) or other regulatory authority approval of, or other action
with respect to, our product candidates, including statements
regarding the timing of any NDA submission; whether issues
identified by FDA in the complete response letter may impact the
potential approvability of the Company’s NDA for AXS-07 for the
acute treatment of migraine in adults with or without aura,
pursuant to our special protocol assessment for the MOMENTUM
clinical trial; the Company’s ability to successfully defend its
intellectual property or obtain the necessary licenses at a cost
acceptable to the Company, if at all; the successful implementation
of the Company’s research and development programs and
collaborations; the success of the Company’s license agreements;
the acceptance by the market of the Company’s products and product
candidates, if approved; the Company’s anticipated capital
requirements, including the amount of capital required for the
continued commercialization of Sunosi and Auvelity and for the
Company’s commercial launch of its other product candidates, if
approved, and the potential impact on the Company’s anticipated
cash runway; unforeseen circumstances or other disruptions to
normal business operations arising from or related to COVID-19; and
other factors, including general economic conditions and regulatory
developments, not within the Company’s control. The factors
discussed herein could cause actual results and developments to be
materially different from those expressed in or implied by such
statements. The forward-looking statements are made only as of the
date of this press release and the Company undertakes no obligation
to publicly update such forward-looking statements to reflect
subsequent events or circumstance.
Axsome Contacts:
Investors:Mark JacobsonChief Operating OfficerAxsome
Therapeutics, Inc.One World Trade Center, 22nd FloorNew York, NY
10007Tel: 212-332-3243Email: mjacobson@axsome.com
www.axsome.com
Media:
Darren OplandDirector, Corporate CommunicationsAxsome
Therapeutics, Inc.One World Trade Center, 22nd FloorNew York, NY
10007Tel: 929-837-1065Email: dopland@axsome.com www.axsome.com
References:
- Substance Abuse and Mental Health Services Administration.
(2022). Key substance use and mental health indicators in the
United States: Results from the 2021 National Survey on Drug
Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH
Series H-57). Rockville, MD: Center for Behavioral Health
Statistics and Quality, Substance Abuse and Mental Health
Services Administration. Retrieved
from https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report.
- National Alliance on Mental
Illness’ Mental Illness Awareness Week homepage. Accessed on
9/30/2023 at
https://www.nami.org/About-NAMI/NAMI-Awards/Scientific-Research-Award.
Axsome Therapeutics (NASDAQ:AXSM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Axsome Therapeutics (NASDAQ:AXSM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024